# Pre-Submission Written Response Request — Q-Sub
## {device_description_short} — Product Code {product_code}

**Date:** {generated_date}
**Requested Meeting Type:** Written Feedback (Q-Submission)
**Product Code:** {product_code} — {classification_device_name}
**Classification:** Class {device_class}, 21 CFR {regulation_number}
**Review Panel:** {review_panel}
**Generated:** {generated_date} | FDA Tools Plugin v5.25.0

---

## 1. Cover Letter

{cover_letter_date}

{review_division_name}
{office_name}
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

**RE: Pre-Submission Q-Sub Request — {device_trade_name}**

Dear Reviewer:

{applicant_name} respectfully requests **written feedback** from FDA regarding our {device_description_short}. We believe this device is classified under product code **{product_code}** (21 CFR {regulation_number}, Class {device_class}).

We have {question_count} well-defined question{s} that we believe can be addressed through written feedback without the need for a formal meeting. These questions focus on:

{question_summary_list}

We are seeking FDA's written response within the standard 75-day review period. Our questions are straightforward and supported by the background information provided in this submission.

Sincerely,

{contact_first_name} {contact_last_name}
{contact_title}
{applicant_name}
{contact_email}
{contact_phone}

---

## 2. Device Overview

### 2.1 Device Description

{device_description}

{device_trade_name} is {device_type_category} intended for {primary_use_summary}.

**Key Features:**
- {feature_1}
- {feature_2}
- {feature_3}

### 2.2 Indications for Use

**Device Trade Name:** {device_trade_name}

**Indications for Use:**

{intended_use}

**Prescription Use:** {rx_otc}

### 2.3 Device Classification

- **Product Code:** {product_code}
- **Classification:** Class {device_class}
- **Regulation:** 21 CFR {regulation_number}
- **Review Panel:** {review_panel}

---

## 3. Proposed Predicate Device(s)

{predicate_analysis_table}

**Primary Predicate:**
- **K-Number:** {primary_predicate_k_number}
- **Device Name:** {primary_predicate_device_name}
- **Applicant:** {primary_predicate_applicant}
- **Decision Date:** {primary_predicate_decision_date}
- **Product Code:** {primary_predicate_product_code}

**Substantial Equivalence Summary:**

{se_rationale_summary}

[TODO: Company-specific — Brief comparison showing same intended use and technological characteristics]

---

## 4. Questions for FDA

{auto_generated_questions}

---

## 5. Supporting Information

### 5.1 Regulatory Pathway

We propose to pursue clearance via the **{proposed_pathway} 510(k)** pathway.

**Rationale:** {pathway_rationale}

### 5.2 Applicable Guidance

We have reviewed the following FDA guidance documents:

- *The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]* (2014)
- {additional_guidance_list}

### 5.3 Applicable Consensus Standards

**FDA-Recognized Consensus Standards:**

{standards_list}

[TODO: Company-specific — List of FDA-recognized consensus standards from `/fda:standards {product_code}`]

---

## 6. Testing Strategy Summary

We propose the following testing to support substantial equivalence:

### 6.1 Biocompatibility (if applicable)

{biocompatibility_testing_plan}

**Proposed Standards:** ISO 10993-1:2018

[TODO: Company-specific — Brief biocompatibility testing plan if device has patient contact]

### 6.2 Performance Testing

{performance_testing_plan}

**Proposed Standards:** {performance_standards_list}

[TODO: Company-specific — Summary of bench testing approach and acceptance criteria]

### 6.3 Sterilization (if applicable)

{sterilization_testing_plan}

**Proposed Standards:** {sterilization_standards}

[TODO: Company-specific — Sterilization validation approach if device is sterile]

### 6.4 Additional Testing

{additional_testing_summary}

[TODO: Company-specific — Other testing categories relevant to questions (electrical, software, shelf life, etc.)]

---

## 7. Background Data

### 7.1 Safety Intelligence

{safety_intelligence_summary}

**Predicate Safety History:**
- **MAUDE Adverse Events (Last 5 Years):** {maude_event_count} events for {primary_predicate_k_number}
- **Recalls:** {recall_count} recalls for product code {product_code} (Last 5 Years)

[TODO: Company-specific — Summary of safety intelligence from `/fda:safety {product_code}`]

### 7.2 Literature Summary

{literature_summary}

[TODO: Company-specific — Summary of relevant clinical literature if supporting questions]

---

## 8. Expected Timeline

- **Q-Sub submission to FDA:** {presub_submission_date}
- **FDA 75-day written response deadline:** {fda_deadline_date}
- **Target 510(k) submission date:** {target_510k_date}

---

## 9. Attachments

[TODO: Company-specific — List all attachments included with this Q-Sub]

1. Device photographs
2. Proposed predicate comparison table
3. Testing protocol summaries (relevant to questions)
4. {additional_attachments}

---

## Disclaimer

> **Important:** This Q-Submission plan is AI-generated from public FDA data and project information. All content should be independently verified by qualified regulatory affairs professionals before submission to FDA. This document does not constitute regulatory advice.

---

**Document Control:**
- **Generated:** {generated_date}
- **Template:** written_response.md
- **Plugin Version:** 5.25.0
- **Project:** {project_name}
- **Meeting Type:** Q-Sub Written Feedback Request
